摘要
目的探讨奥美拉唑、伊托必利结合阿卡波糖治疗老年慢性胃炎合并血糖异常的疗效及对高密度脂蛋白(HDL-C)、糖化血红蛋白(HbAlc)水平的影响。方法选取2019年6月至2022年6月于安徽省合肥庐江县人民医院就诊的92例老年慢性胃炎合并血糖异常患者,患者均采用医生主导的饮食干预方案,并且根据用药方案将患者分为观察组(予奥美拉唑、伊托必利结合阿卡波糖治疗,n=46)和对照组(予奥美拉唑结合伊托必利治疗,n=46)。比较两组的临床疗效、血糖指标、幽门螺杆菌(Hp)清除率变化情况、不良反应发生率以及HDL-C、HbAlc水平。结果观察组的总有效率为97.83%明显高于对照组的82.61%,差异具有统计学意义(χ^(2)=4.434,P<0.05)。治疗后,观察组的空腹血糖(FPG)、餐后2h血糖(2 hPG)、HbAlc水平明显低于对照组,HDL-C水平明显高于对照组,差异具有统计学意义(t=5.324、2.807、3.677、2.241,P<0.05)。观察组的Hp清除率为97.83%明显高于对照组的80.43%,差异具有统计学意义(χ^(2)=7.181,P<0.05)。观察组的不良反应总发生率为4.35%,明显低于对照组的17.39%,差异具有统计学意义(χ^(2)=4.039,P<0.05)。结论奥美拉唑、伊托必利结合阿卡波糖治疗老年慢性胃炎合并血糖异常具有明显的临床疗效,能够明显降低患者的血糖水平并清除幽门螺杆菌,不良反应少,且能够升高HDL-C水平并降低HbAlc水平。
Objective To investigate the efficacy of omeprazole,etopride and acarbose in the treat⁃ment of elderly chronic gastritis with abnormal blood glucose and their effects on the levels of high⁃density lipo⁃protein(HDL⁃C)and glycosylated hemoglobin(HbAlc).Methods A total of 92 elderly patients with chronic gastritis combined with abnormal blood glucose were selected from June 2019 to June 2022.All patients were treated with doctor⁃led dietary intervention,and were divided into the observation group(omeprazole,itopride combined with acarbose,n=46)and the control group(omeprazole combined with itopride,n=46).The clini⁃cal efficacy,blood glucose index,the change of Helicobacter pylori(Hp)clearance,the incidence of adverse reactions and the levels of HDL⁃C and HbAlc were compared between the two groups.Results The total effective rate in the observation group was 97.83%,which was significantly higher than that in the control group(82.61%)(χ^(2)=4.434,P<0.05).After treatment,the fasting blood glucose(FPG),2h postprandial blood glu⁃cose(hPG)and HbAlc levels in the observation group were significantly lower than those in the control group,while HDL⁃C levels were significantly higher than those in the control group,with statistically significant differ⁃ences(t=5.324,2.807,3.677,2.241,P<0.05).The clearance rate of Hp in the observation group was 97.83%,which was significantly higher than that in the control group(80.43%)(χ^(2)=7.181 P<0.05).The total incidence of adverse reactions in the observation group was 4.35%,which was significantly lower than that in the control group(17.39%),with a statistically significant difference(χ^(2)=4.039,P<0.05).Conclusion Omeprazole,Ito⁃pride and Acarbose have obvious clinical efficacy in the treatment of elderly chronic gastritis with abnormal blood glucose,which can significantly reduce the blood glucose level of patients and eliminate Helicobacter pylori,with less adverse reactions,and can increase the HDL⁃C level and reduce the HbAlc level.
作者
孔玲玲
张中唐
任婷婷
KONG Lingling;ZHANG Zhongtang;REN Tingting(Department of Pharmacy,Lujiang County People's Hospital,Lujiang,Anhui,China,231500)
出处
《分子诊断与治疗杂志》
2023年第5期867-870,共4页
Journal of Molecular Diagnostics and Therapy
基金
安徽省重点研究与开发计划项目(1704f0804023)。
